Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non- small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing.

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

ALK FISH and IHC: You Cannot Have One without the Other

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer Katsuyuki Kiura,

A Case of Heart Failure after Treatment with Anti–PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient

Treatment of Pulmonary Epithelioid Hemangioendothelioma with Bevacizumab Young Hak Kim, MD, Michiaki Mishima, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD

Electronic Updates for JTO Readers

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study Kaoru Kubota, MD, PhD,

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib Sai-Hong Ignatius Ou, MD, PhD,

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure Jessamy A. Boyd, MD, Jessica L. Hubbs,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non– Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI Akito Hata,

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Phase I Study of Amrubicin and Fixed Dose of Irinotecan (CPT-11) in Relapsed Small Cell Lung Cancer: Japan Multinational Trial Organization LC0303

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Bilateral Subdural Hematoma Associated with Central Nervous System Metastases from Lung Cancer Akito Hata, MD, Shiro Fujita, MD, PhD, Nobuyuki Katakami,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Pharmacokinetics of Multiple-Dose Levofloxacin in Hemodialysis Patients Shuichi Tsuruoka, MD, PhD, Noritsugu Yokota, MD, PhD, Tokie Hayasaka, RN, Tetsuo.

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer Nami.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma Mitchell Machtay, MD, Rebecca Paulus, BS, Jennifer.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in.

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Angiosarcoma Arising from Right Atrium: Remarkable Response to Concurrent Chemoradiotherapy with Carboplatin and Paclitaxel Akito Hata, MD, Nobuyuki.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Ethnic Differences in the Management of Lung Cancer in New Zealand

European Lung Cancer Conference (ELCC) 2016 Organisation

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Pleural Metastases of Malignant Melanoma

Novel Drugs—Miscellaneous Category

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Successful Treatment with Pemetrexed in a Patient with Mucinous Bronchioloalveolar Carcinoma: Long-Term Response Duration with Mild Toxicity Chiyuki.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Sleeve Lobectomy as an Alternative Procedure to Pneumonectomy for Non-small Cell Lung Cancer Joon Suk Park, MD, Hee Chul Yang, MD, Hong Kwan Kim, MD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non- small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis Yosuke Togashi, MD, Katsuhiro Masago, MD, PhD, Masahide Fukudo, PhD, Tomohiro Terada, PhD, Yasuaki Ikemi, BPharm, Young Hak Kim, MD, Shiro Fujita, MD, PhD, Kaoru Irisa, MD, Yuichi Sakamori, MD, Tadashi Mio, MD, PhD, Ken-ichi Inui, PhD, Michiaki Mishima, MD, PhD Journal of Thoracic Oncology Volume 5, Issue 5, Pages 601-605 (May 2010) DOI: 10.1097/JTO.0b013e3181d32287 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Plasma concentration-time plots of erlotinib and OSI-420 in HD 1 on day 1 (off HD), day 8 (off HD) and day 9 (on HD). Arrows indicate 150 mg erlotinib administration. HD, hemodialysis. Journal of Thoracic Oncology 2010 5, 601-605DOI: (10.1097/JTO.0b013e3181d32287) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Plasma concentration-time plots of erlotinib and OSI-420 in HD 2 on day 1 (off HD), day 8 (off HD) and day 9 (on HD). Arrows indicate 150 mg erlotinib administration. HD, hemodialysis. Journal of Thoracic Oncology 2010 5, 601-605DOI: (10.1097/JTO.0b013e3181d32287) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Plasma concentration-time plots of erlotinib and OSI-420 in HD 3 on day 1 (off HD), day 8 (off HD) and day 9 (on HD). Arrows indicate 150 mg erlotinib administration. HD, hemodialysis. Journal of Thoracic Oncology 2010 5, 601-605DOI: (10.1097/JTO.0b013e3181d32287) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Mean plasma concentration-time plots (± standard deviation) of erlotinib and OSI-420 in the control group on day 1 and day 8 and those in the HD group on day 1, day 8, and day 9. HD shows hemodialysis. The patterns in the HD group were similar to those in the control group. Journal of Thoracic Oncology 2010 5, 601-605DOI: (10.1097/JTO.0b013e3181d32287) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions